Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Hong Kong King-Friend Pays $40 Million for Global Rights to Humira Biosimilar

publication date: Jun 27, 2024

Hong Kong King-Friend Industry bought global rights to Yusimry®, a Humira® biosimilar, from Coherus BioSciences of Redwood City, CA for an upfront cash payment of $40 million. HKF awarded US rights for the biosimilar to its US subsidiary, Chicago’s Meitheal Pharma. The acquisition adds a fifth biosimilar and the first marketed biosimilar to Meitheal’s portfolio, which has invested over $300 million in capital and R&D to build its portfolio, including a $30 million mAb drug substance facility. Coherus, once a partner for China-developed biosimilars, now focuses on immune-oncology candidates. More details....

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here